MAXHEALTH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | MAXHEALTH | Market Cap | 1,06,127 Cr. | Current Price | 1,090 ₹ | High / Low | 1,314 ₹ |
| Stock P/E | 146 | Book Value | 91.9 ₹ | Dividend Yield | 0.14 % | ROCE | 10.5 % |
| ROE | 8.46 % | Face Value | 10.0 ₹ | DMA 50 | 1,011 ₹ | DMA 200 | 1,049 ₹ |
| Chg in FII Hold | -5.16 % | Chg in DII Hold | 5.12 % | PAT Qtr | 203 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 69.7 | MACD | 8.83 | Volume | 75,81,080 | Avg Vol 1Wk | 26,20,912 |
| Low price | 903 ₹ | High price | 1,314 ₹ | PEG Ratio | 88.3 | Debt to equity | 0.09 |
| 52w Index | 45.6 % | Qtr Profit Var | 14.6 % | EPS | 7.36 ₹ | Industry PE | 45.6 |
📈 Positive
- EPS at ₹7.36 provides earnings visibility.
- Dividend yield (0.14%) offers modest income support.
- Debt-to-equity ratio (0.09) reflects low leverage.
- DII holdings increased (+5.12%), showing strong domestic institutional confidence.
- PAT growth (₹200 Cr. → ₹203 Cr.) indicates steady profitability.
- RSI (69.7) and MACD (8.83) show strong momentum near highs.
⚠️ Limitation
- Very high P/E (146 vs industry 45.6) signals overvaluation.
- ROCE (10.5%) and ROE (8.46%) are modest, limiting efficiency appeal.
- PEG ratio (88.3) highlights unsustainable valuation relative to growth.
- Current price (₹1,090) is near resistance levels (₹1,314), limiting upside.
- FII holdings declined (-5.16%), reflecting reduced foreign investor confidence.
📉 Company Negative News
- Decline in foreign institutional participation raises concerns.
- Elevated valuation multiples may restrict near-term returns.
📊 Company Positive News
- Domestic institutional inflows show strong local support.
- Technical strength above DMA 50 (₹1,011) and DMA 200 (₹1,049).
- Consistent PAT growth supports earnings stability.
🏭 Industry
- Healthcare sector benefits from rising demand and defensive positioning.
- Industry PE (45.6) is far below Max Healthcare’s valuation, highlighting premium pricing.
- Sector outlook remains positive with long-term demand drivers.
✅ Conclusion
- Current price (₹1,090) is supported by DMA levels but trades at a steep premium.
- **Ideal Entry Zone:** ₹1,000 – ₹1,050 (aligned with DMA support and valuation comfort).
- **Exit Strategy (if already holding):** Consider partial profit booking near ₹1,280–₹1,300; hold remainder for 2–3 years if ROE/ROCE improve.
- Long-term holding is viable only if profitability strengthens and valuation premium moderates.
Max Healthcare shows strong momentum and institutional support but trades at a steep premium relative to industry peers. Tactical entries near support zones improve risk-reward, while staggered exits near resistance help manage exposure.
Would you like me to extend this into a peer benchmarking analysis, a sector overlay comparison, or a long-term holding roadmap?